Hinge Health Inc. HNGE
95.57
3.59
3.90%
as of 25 Sep
- Market cap
- $7.4B
- P/E
- 70.8×
Follow HNGE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+6 more quarters Free account |
0.00 | 0.00 | 0.00 | 61.48 |
P/S ratio |
7.48 | 4.31 | 4.69 | 9.10 | |
P/FCF ratio |
27.36 | 15.33 | 14.95 | 23.09 | |
P/Operating CF |
46.97 | 39.68 | 70.37 | 64.63 | |
P/B ratio |
18.61 | 14.19 | 27.14 | 19.04 | |
Price to Tangible BV |
27.42 | 22.62 | 66.92 | 23.56 | |
EV/Sales |
6.55 | 3.69 | 4.20 | 8.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 38.24 | |
EV/Operating CF |
23.24 | 12.66 | 12.96 | 21.20 | |
EV/FCF |
23.96 | 13.13 | 13.39 | 21.71 | |
Quick Ratio |
1.59 | 1.19 | 1.04 | 1.07 | |
Current Ratio |
1.85 | 1.47 | 1.30 | 1.34 | |
Net Debt/EBITDA |
(61.64) | (8.52) | (6.37) | (6.37) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.35 | 1.58 | 1.77 | 0.95 | |
Operating CF/Net income |
(44.68) | 1.99 | 1.27 | 2.35 | |
Capex/Depreciation |
(0.08) | (0.15) | (0.09) | (0.09) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
20.70% | 19.19% | 16.64% | 16.00% | |
Selling, General and Administrative Expense of Revenue |
65.09% | 49.21% | 50.37% | 51.43% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.09 | 0.08 | |
Share Based Compensation of Revenue |
22.60% | 10.06% | 6.41% | 8.97% | |
Graham Net Nets |
0.03 | (0.01) | (0.03) | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 11.51 | |
Earnings Yield |
(24.40%) | (25.00%) | (31.90%) | 1.63% | |
Free Cash Flow Yield |
3.66% | 6.52% | 6.69% | 4.33% | |
Revenue per Share |
1.96 | 3.13 | 2.32 | 2.69 | |
Operating CF per Share |
1.04 | 1.17 | 0.55 | 1.28 | |
Capex per Share |
(0.01) | (0.04) | (0.02) | (0.02) | |
Free Cash Flow per Share |
1.03 | 1.13 | 0.53 | 1.26 | |
Cash per Share |
6.09 | 6.67 | 4.02 | 4.93 | |
Shareholders Equity per Share |
2.64 | 3.27 | 1.42 | 4.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.64 | 3.27 | 1.42 | 4.36 | |
Free Cash Flow |
81.28 | 61.53 | 41.55 | 99.56 | |
Working Capital |
301.81 | 171.50 | 125.58 | 161.91 | |
Capital Expenditures |
(1.12) | (2.36) | (1.53) | (1.85) | |
Net Current Asset Value |
97.08 | (32.19) | (77.03) | 160.28 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 65.82 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(1.20%) | 18.80% | 18.66% | 20.25% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 69.97 | |
| Other line items | |||||
Average Receivables |
— | 56.31 | 78.71 | 112.37 | |
Average Payables |
— | 48.19 | 48.66 | 47.81 | |
Average Inventory |
— | 14.46 | 12.52 | 15.38 | |
Average Assets |
384.90 | 372.38 | 364.39 | 760.53 | |
Average Common Equity |
— | (122.67) | (161.44) | 259.05 |
Columns are period end dates